For metastatic GIST, KIT‐inhibitors (e.g., imatinib or avapritinib) (anti‐KIT/PDGFRA) or other anti‐angiogenic (e.g. sunitinib) agents are available and effective to control the disease. Here, KIT is linked to gastrointestinal stromal tumor.